The North America Molecular Quality Controls Market would witness Market growth of 6.3% CAGR during the forecast period (2022-2028).
The molecular quality controls Market is majorly driven by a shift in Market players' focus toward creating molecular diagnostic tests for infectious disease detection and cancer detection; an increase in end-user adoption of third-party quality controls, growth in the number of credentialed clinical laboratories, and a rising demands for external quality assessment support. Industry growth is also boosted by Market players' focus on new launches and alliances to increase their product portfolio and regional presence. Microbiologics, for example, released a number of quality control products in 2018, including an enteric virus control panel, a vaginal verification panel, a blood culture control panel, and a vaginal control panel. For example, Seracare partnered with AccuRef Diagnostics to commercialize the latter's range of CRISPR-engineered cell line reference materials in the same year.
Market trends in molecular quality controls across the region are fueled by a number of reasons, including the steady increase in the number of accredited clinical laboratories. On the basis of results from an on-site inspection done as part of the CAP's Accreditation Programs, the CAP (College of American Pathologists) conferred accreditation to UC Berkeley's Innovative Genomics Institute Clinical Laboratory in September 2021. This increase in healthcare facilities will create an urgent need for extensive monitoring and testing of diagnostic goods for potential anomalies, which could drive up demand for molecular quality control solutions in the coming years.
According to a report published by the Joint United Nations Programme on HIV and AIDS (UNAIDS) in 2021, 28.2 million persons living with HIV had access to antiretroviral medication around the world. Additionally, growing government participation in controlling infectious disease outbreaks and rising demand for quality assessment support and fast diagnosis systems are likely to contribute to the regional Market 's growth during the forecast period.
The US Market dominated the North America Molecular Quality Controls Market by Country 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $73.3 million by 2028. The Canada Market is anticipated to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico Market would display a CAGR of 7.8% during (2022 - 2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Molecular Quality Controls Market is Estimated to reach $259.4 Million by 2028, at a CAGR of 6.6%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
By Analyte Type
By Application
By Product
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
